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Abstract
Malaria is caused by infection with intraerythrocytic protozoa of the genus Plasmodium that are transmitted by Anopheles
mosquitoes. Although a variety of anti-parasite effector genes have been identified in anopheline mosquitoes, little is
known about the signaling pathways that regulate these responses during parasite development. Here we demonstrate
that the MEK-ERK signaling pathway in Anopheles is controlled by ingested human TGF-b1 and finely tunes mosquito innate
immunity to parasite infection. Specifically, MEK-ERK signaling was dose-dependently induced in response to TGF-b1i n
immortalized cells in vitro and in the A. stephensi midgut epithelium in vivo. At the highest treatment dose of TGF-b1,
inhibition of ERK phosphorylation increased TGF-b1-induced expression of the anti-parasite effector gene nitric oxide
synthase (NOS), suggesting that increasing levels of ERK activation negatively feed back on induced NOS expression. At
infection levels similar to those found in nature, inhibition of ERK activation reduced P. falciparum oocyst loads and infection
prevalence in A. stephensi and enhanced TGF-b1-mediated control of P. falciparum development. Taken together, our data
demonstrate that malaria parasite development in the mosquito is regulated by a conserved MAPK signaling pathway that
mediates the effects of an ingested cytokine.
Citation: Surachetpong W, Singh N, Cheung KW, Luckhart S (2009) MAPK ERK Signaling Regulates the TGF-b1-Dependent Mosquito Response to Plasmodium
falciparum. PLoS Pathog 5(4): e1000366. doi:10.1371/journal.ppat.1000366
Editor: David S. Schneider, Stanford University, United States of America
Received October 24, 2008; Accepted March 5, 2009; Published April 3, 2009
Copyright:  2009 Surachetpong et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by funding from the National Institute of Allergy and Infectious Diseases (NIAID) National Institutes of Health (NIH) AI050663
to S.L. These studies were conducted in a facility constructed with support from C06 RR-12088-01 from the National Center for Research Resources, NIH. W.S. is
supported by the Royal Thai Government Scholarship. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of
the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: sluckhart@ucdavis.edu
Introduction
Approximately 300 to 500 million malaria cases and 1 to 3
million deaths are reported annually, with the greatest numbers of
deaths occurring in sub-Saharan Africa following infection with
Plasmodium falciparum [1]. The increasing prevalence of insecticide-
resistant Anopheles and drug-resistant malaria parasite strains has
negatively impacted malaria control. As such, alternative malaria
control strategies including the development of transgenic
mosquito lines refractory to malaria parasite transmission have
been explored [2,3]. Studies of mosquito innate immunity have
identified potential genes and molecules that are involved in
parasite killing [4–7]. For example, inducible expression of nitric
oxide synthase (NOS) and production of toxic nitrogen oxides as well
as a variety of other anti-parasite effectors in the mosquito midgut
[4,7–9] – a critical tissue for early parasite development – suggest
that the midgut response could be targeted to enhance anti-
parasite resistance. In support of this concept, published data have
confirmed that genetic manipulation of the NF-kB-dependent Toll
and Imd signaling pathways can alter development of the murine
parasite Plasmodium berghei in the African malaria vector Anopheles
gambiae [10,11]. Manipulation of cell signaling pathways in this
way can facilitate the regulation of a large number of anti-parasite
effectors in concert, minimizing the likelihood that the parasite
could adapt to an altered host [12].
During blood digestion in the Asian malaria mosquito Anopheles
stephensi, crosstalk between ingested human transforming growth
factor (TGF)-b1 and cells of the midgut epithelium induces
responses that protect the mosquito against malaria parasite
infection [13,14]. This anti-malarial response is mediated in part
by TGF-b1-inducible NOS which catalyzes the production of
reactive nitrogen oxides that are toxic to the parasite [4,7]. We
have identified orthologous TGF-b receptors and Smad signaling
proteins in A. stephensi and in A. gambiae [15], suggesting that
conserved signaling pathways could support a functional signaling
framework for immunological crosstalk between human TGF-b1
and Anopheles cells. However, the full complement of mosquito cell
signaling pathways that are activated by TGF-b1 and how this
activation controls the anti-parasite response in the mosquito
remain to be determined.
Transforming growth factor-b1 is a member of the TGF-b
superfamily of cytokines, which are known to regulate cell
differentiation, proliferation, apoptosis and pro- and anti-inflam-
matory immune responses [16,17]. Given these broad biological
effects, it is not surprising that TGF-b1 is a pivotal regulator of the
mammalian response to malaria parasite infection, having been
described as maintaining ‘‘immunological balance’’ during
infection [18]. In mammalian cells, TGF-b1 signaling is mediated
through the type I and II serine/threonine kinase receptors. After
ligand binding, the TGF-b receptor complex recruits and activates
SMAD signaling proteins [19]. This activation induces transloca-
tion of the activated SMAD complex into the nucleus where it
regulates gene expression [20]. In addition to the SMAD signaling
pathway, TGF-b1 activates other signaling proteins, particularly
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MAPK signaling cascades are comprised of three protein kinases:
a MAPKKK that phosphorylates and activates a MAPKK (e.g.,
MEK) which subsequently phosphorylates and activates a MAPK
(e.g., ERK) that can regulate transcription factor activity and gene
expression. The MAPKs are serine/threonine kinase signaling
proteins that are responsive to stress, inflammatory mediators, and
growth factors. All three of the MAPKs, including extracellular
signal regulated kinase (ERK), c-Jun N-terminal kinase (JNK) and
p38 MAPK have been implicated in the mammalian innate
immune response to malaria infection [24–26] and all three are
activated by TGF-b1 [27]. Cellular activation by TGF-b1
regulates both SMAD-dependent as well as SMAD-independent
MAPK-regulated transcriptional responses [22,28,29]. Based on
these observations, we hypothesized that MAPK signaling
regulates the mosquito immune response to malaria parasite
infection and that TGF-b1 ingested with the blood meal finely
tunes this response. We have confirmed this hypothesis and
suggest that our work can synergize with current efforts to target
MAPKs for human genetic and infectious diseases. Small molecule
MAPK agonists and antagonists can be used to unravel MAPK
regulation of mosquito innate immunity and could be adapted to
specifically target the mosquito host to enhance signaling through
a MAPK pathway that is critical to anti-parasite defense.
Materials and Methods
Reagents
Human recombinant TGF-b1 was obtained from R&D Systems
(Minneapolis, Minnesota). Monoclonal anti-diphosphorylated
ERK1/2 was purchased from Sigma-Aldrich (St. Louis, Missouri)
and polyclonal anti-ERK1/2 antibodies were purchased from Cell
Signaling Technology (Charlottesville, Virginia). Anti-phospho
p38 MAPK antibody was obtained from Cayman Chemical (Ann
Arbor, Michigan), anti-phospho JNK1&2 antibody from Bio-
source (Camarillo, California), and anti-GAPDH antibody from
Abcam (Cambridge, Massachusetts). Horseradish peroxidase-
conjugated polyclonal rabbit anti-mouse IgG was purchased from
Sigma-Aldrich and horseradish peroxidase-conjugated goat anti-
rabbit F(ab’)2 fragment was purchased from Biosource Interna-
tional (Camarillo, California). The MEK1/2 inhibitors PD98059
and U0126 were obtained from Sigma-Aldrich and from Promega
(Madison, Wisconsin), respectively. The BCA assay kit and
SuperSignal West Pico chemiluminescent detection kit were
purchased from Pierce (Rockford, Illinois). Human serum and
erythrocytes were purchased from Interstate Blood Bank (Mem-
phis, Tennessee). RPMI 1640 with HEPES was purchased from
Gibco/Invitrogen (Carlsbad, California). All other chemicals and
reagents were obtained from Sigma-Aldrich or Fisher Scientific.
Cell culture, mosquito rearing, and mosquito feeding
The immortalized, embryo-derived A. stephensi ASE cell line [30]
was maintained in modified minimal essential medium (MEM;
Gibco, Invitrogen, Carlsbad, California) with 5% heat-inactivated
fetal bovine serum at 28uC under 5% CO2. The immortalized,
minced larvae-derived A. gambiae 4a3B cell line was kindly
provided by Hans-Michael Muller, EMBL [31]. 4a3B cells were
maintained in Schneider’s medium (Invitrogen) with 10% heat-
inactivated fetal bovine serum at 28uC.
For in vivo studies, A. stephensi Liston (Indian wild-type strain)
were reared and maintained at 27uC and 75% humidity. All
mosquito rearing protocols were approved and in accord with
regulatory guidelines and standards set by the Institutional Animal
Care and Use Committee of the University of California, Davis.
Laboratory reared 3–5 day old female mosquitoes were allowed to
feed for 20 min on reconstituted human blood meals (hereafter
known as ‘‘artificial blood meals’’) provided through a Hemotek
Insect Feeding System (Discovery Workshops, Accrington, UK).
Artificial blood meals contained washed human erythrocytes and
saline (10 mmol l
21 NaHCO3,15 mmol l
21 NaCl, 1 mmol l
21
ATP, pH 7.0) with or without human recombinant TGF-b1a t2 ,
20, 200, 2000 pg/mL and with or without PD98059 at 4 or
40 mM. For western blot analyses, midguts were dissected from
100 mosquitoes in each treatment and control group and
processed as previously described [32]. Control mosquitoes were
provided artificial blood meals supplemented with an equivalent
volume of diluent. Protocols involving the culture and handling of
P. falciparum for mosquito feeding were approved and in accord
with regulatory guidelines and standards set by the Biological
Safety Administrative Advisory Committee of the University of
California, Davis.
Immunoblotting
Protein extracts of ASE and 4a3B cells were prepared by
collecting cells in lysis buffer as previously described [33]. Briefly,
2610
6 cells in 2 mL medium were plated in 12 well tissue culture
plates overnight for ASE cells or 4 h for 4a3B cells. After treatment,
culture media were removed and cells were washed with ice cold
PBS and lysed in 100 mL cell lysis buffer (10 mM Tris-HCl pH 7.4,
1 mM EDTA, 100 mM NaCl, 1 mM NaF, 1 mM EGTA, 2 mM
Na3VO4,2 0m MN a 4P2O7, 0.1% SDS, 1% Triton X-100, 0.5%
sodium deoxycholate, 1 mM phenylmethylsulfonyl fluoride, 10%
glycerol, 60 mg/mL aprotinin, 10 mg/ml leupeptin, 1 mg/ml
pepstatin, and 1 mg/ml calyculin A). Cell lysates were cleared at
14,000 g for10 minandtheresultingsupernatantsweremixedwith
sample buffer (125 mM Tris-HCl pH 6.8, 10% glycerol, 10% SDS,
0.006% bromophenol blue, 130 mM dithiothreitol) and heated to
95uC for 4 min. Equivalent concentrations of proteins (as measured
by BCA assay) were separated on 10% SDS-PAGE polyacrylamide
gels and transferred to nitrocellulose membranes (BioRad). Protein
loading was also visually assessed by Coomassie blue staining.
Membranes were blocked in 5% nonfat dry milk (w/v) in 16Tris-
buffered saline (TBS; pH 7.0) containing 0.1% Triton-100 (TBS-T)
1 h at room temperature. For ERK detection, membranes were
incubated at 4uC overnight with 1:10,000 mouse anti-phospho-
ERK monoclonal antibody or with 1:1,000 rabbit anti-ERK
polyclonal antibody in 5% nonfat dry milk 16 TBS-T. For
detection of phospho-p38 MAPK, phospho-JNK, and GAPDH
Author Summary
To date, malaria remains an enormous public health
burden, especially in developing countries. New strategies,
including integrated vector management in combination
with current conventional malaria control efforts such as
drug treatment and bednet usage, could synergistically
reduce malaria transmission. However, our current knowl-
edge of vector–host–parasite interactions is limited. For
example, how mosquito innate immune responses control
malaria parasite development and how blood-derived
factors modulate mosquito biology remain interesting
topics. In this paper, we reveal the role of MEK-ERK
signaling in the regulation of malaria parasite develop-
ment by an ingested blood-derived, mammalian cytokine
in the mosquito host. Our results provide new insights into
the host–parasite–vector relationship that could be
utilized as a foundation for new strategies to reduce
malaria transmission.
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rabbit anti-phospho p38 MAPK antibody or with 1:1,000 rabbit
anti-phospho JNK1&2 antibody, or with 1:10,000 rabbit anti-
GAPDH antibody in 5% BSA 16 TBS-0.1%Tween 20. Mem-
branes were washed 3 times, 5 min each, and incubated with a
1:25,000 dilutionof HRP-conjugated rabbitanti-mouseIgGor with
a 1:20,000 dilution of HRP-conjugated goat anti-rabbit (Fab’)2
fragment at 4uC overnight. To reveal antibody-bound proteins,
membranes were incubated with SuperSignal West Pico chemilu-
minescent reagent for 2 min. Each membrane was exposed to blue
autoradiography film (ISC Bioexpress, Kaysville, Utah). Phospho-
MAPK levels and total ERK levels were measured on scanned film
using a GS-800 calibrated densitometer (BioRad, Hercules,
California). Levels of phospho-MAPKs in each treatment were
normalized to the appropriate control group.
Real-time quantitative PCR
Total RNAs were isolated from cultured cells or from pools of 15
mosquito midguts from each treatment and control group using
Trizol reagent (Invitrogen) at 6 h to 48 h after treatment. Samples
were analyzed by quantitative RT-PCR using an ABI Prism 7300
Sequence Detection System (Applied Biosystems; Foster City,
California). NOS expression levels were normalized against S7
ribosomal protein gene expression levels as previously described [36]
and are represented as the fold induction over control. Primers
and probes used for amplification included: AgNOS forward,
59CCTGATCGGTCCCGGTACT39; AgNOS reverse, 59AATT-
GGCAACATTCCACATACCTT39; AsNOS forward, 59GAC-
CAAACCGGTCATCCTGAT39; AsNOS reverse, 59GGAATCT-
TGCAGTCAACCATTTC39; S7 forward, 59GAAGGCCTTC-
CAGAAGGTACAGA39;a n dS7 reverse, 59CATCGGTTTGGG-
CAGAATG39. NOS probe, 6-carboxyfluorescein-CACCGTT-
CCGTTCGTTCTGGCA-6 carboxytetramethylrhodamine; and
S7 probe, VIC-AGAAGTTCTCCGGCAAGCACGTCGT-6-car-
boxytetramethylrhodamine. Complementary DNAs and amplimers
were generated from sample RNAs using MuLV reverse transcrip-
tase in TaqManH Gold RT-PCR assays (Applied Biosystems).
Thermal cycling conditions were as follows: 30 min at 50uC, 10 min
at 95uC, and 40 cycles of 15 s at 95uCa n d1m i na t6 0 uC. Duplicate
reactions with 100 ng template RNA were analyzed simultaneously
with no template controls.
Plasmodium falciparum culture, mosquito feeding and
analysis of infection intensity
Cultures of P. falciparum NF54 were initiated at 1% parasitemia in
10% heat-inactivated human serum, and 6% washed human RBCs
in RPMI 1640 with HEPES (Gibco) and hypoxanthine. At day 15–
17, stage V gametocytes were evident and exflagellation was
evaluated on the day prior to feeding and on the day of feeding. For
our assays, 5-day old A. stephensi were fed on mature gametocyte
culture dilutedwithhumanerythrocytesand heat-inactivated serum
with or without human recombinant TGF-b1 and with or without
PD98059. All treatments were added to the diluted P. falciparum
culture immediately prior to feeding. On day 8, mosquito midguts
were dissected in PBS and stained with mercurochrome for direct
counting of P. falciparum oocysts. Mean oocysts per midgut in each
treatment group were calculated from all dissected mosquitoes
(including zeros for mosquitoes that contained no oocysts).
Plasmodium falciparum parasite growth inhibition assay
Aliquots of a single culture of P. falciparum NF54 were plated in 96
well flat bottom plates in complete RPMI 1640 with HEPES,
hypoxanthine and 10% heat inactivated human serum. Parasites
were treated with 0.004% or 0.4% DMSO (PD98059 diluent), with
0.4, 4.0 or 40 mM PD98059, with 20 or 2000 pg/ml human TGF-
b1,withPBS (TGF-b1 diluent) at a volume equivalent tothehighest
concentration of TGF-b1 used, with 2000 pg/ml human TGF-b1
plus 40 mM PD98059, or with 10 nM or 100 nM chloroquine
phosphate (Sigma-Aldrich) for 50 hr in a candle jar. The assay was
terminated by adding formaldehyde to a final concentration of 1%.
Erythrocytes were diluted into PBS containing 1% Triton X-100
and were stained with 1 nM YOYO-1, a fluorescent dye that
intercalates into DNA and, therefore, labels parasite-infected RBCs
[37]. Infected RBCs were counted with a FACS cell sorter, Becton
Dickinson (Franklin Lakes, New Jersey). Growth assays were
performed in triplicate within each assay and were also replicated
with independent cultures of P. falciparum. Relative parasite growth
is represented as percentages of parasite numbers in the PBS
control, which was set at 100%.
Statistical analyses
The Kolmogorov-Smirnov test was used to determine normality
(Biostat 2007, AnalystSoft, Washington, DC). Data that were
normally distributed were analyzed by ANOVA (a=0.05) for
overall significance and by Student-Neuman-Keuls for pairwise
comparisons using Graphpad Prism version 4.0 (San Diego,
California) or Student’s t-test to assess differences between
experimental groups at specific time intervals. Prevalences of
mosquito infection were analyzed by chi-square (a=0.05).
Results
Human TGF-b1 activates ERK signaling in mosquito cells
To determine whether ERK signaling was involved in the TGF-
b1-induced anti-malarial response in mosquito cells, we assayed
two Anopheles mosquito cell lines – ASE and 4a3B – for their
response patterns. Cells were treated with doses of active human
TGF-b1 that are in the range of concentrations (low pg/mL to low
ng/mL) that have been detected in P. falciparum-infected patients
[38–41], that bracketed blood-derived concentrations that we have
detected in A. stephensi [13] and that we have analyzed for NOS
induction patterns in the mosquito midgut [14]. Lysates from
treated cells were analyzed by western blotting for phospho-ERK
and total ERK levels. In ASE cells, human TGF-b1 dose
dependently activated ERK phosphorylation (Figure 1A). Follow-
ing TGF-b1 treatment, ERK phosphorylation was evident within
5 min, but was reduced at 15 min and below basal levels at
60 min after treatment (Figure 1B). In 4a3B cells, 60 pg/mL
TGF-b1 maximally induced ERK phosphorylation at 15 min and
activation persisted for at least 60 min after treatment (Figure 1C).
Based on our in vitro results, we sought to determine whether
human TGF-b1 could induce ERK activation in vivo in the
mosquito midgut. Five day old female A. stephensi mosquitoes were
fed on artificial blood meals supplemented with doses of human
TGF-b1 that spanned the range of concentrations used for cell
stimulation. As shown in Figure 1D, ingested human TGF-b1
dose-dependently induced ERK phosphorylation in the A. stephensi
midgut with the highest induction observed at 2000 pg/mL TGF-
b1. Interestingly, we also observed that the artificial blood meal
(BM) alone induced ERK phosphorylation up to 2-fold relative to
non-bloodfed insects (no blood meal or NBM) suggesting that
factors from human erythrocytes or perhaps blood ingestion and
midgut expansion can induce MAPK signaling in mosquito cells.
TGF-b1-induced ERK phosphorylation is MEK-dependent
To determine whether ERK activation was involved in TGF-b1
induction of NOS gene expression, we pre-treated cells with one of
MEK-ERK Control of P. falciparum Sporogony
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studies prior to stimulation with human TGF-b1. These inhibitors
– PD98059 and U0126 – specifically inhibit MEK1/2, an
upstream activator of ERK and, thus, prevent ERK phosphory-
lation. We first examined the effects of PD98059 on ERK
activation in A. gambiae 4a3B cells. As shown in Figure 2A,
PD98059 dose-dependently inhibited TGF-b1-induced ERK
phosphorylation in 4a3B cells with complete inhibition observed
at 40 mM PD98059. In ASE cells, ERK phosphorylation was
notably reduced at 4 mM PD98059 and completely inhibited at
10 mM PD98059 (Figure 2B). Indeed, PD98059 potently inhibited
both background ERK phosphorylation and TGF-b1-induced
ERK phosphorylation in ASE cells (Figure 2B) and, in 4a3B cells,
this inhibition was sustained through at least 6 h after treatment
(Figure 2C).
To determine whether ERK activation by TGF-b1 regulated
mosquito NOS gene expression, we monitored NOS expression in
4a3B cells that were treated with PD98059 or TGF-b1 alone at
doses as in Figure 2C, pre-treated with PD98059 and stimulated
with TGF-b1, or treated with PBS (TGF-b1 diluent) or DMSO
(PD98059 diluent) as controls. In replicated experiments, inhibi-
tion of ERK phosphorylation increased mean TGF-b1-dependent
NOS induction at 6 h to 3.0- to 3.2-fold relative to PBS and
DMSO controls and to 1.8- to 2.1-fold relative to TGF-b1 and
PD98059 alone (Figure 2D). Inhibition of ERK phosphorylation
did not increase mean TGF-b1-dependent NOS induction at 24 h
or 48 h after treatment in 4a3B cells (not shown).
To confirm that ERK activation negatively regulated TGF-b1-
induced NOS expression, we repeated the assays with a second
MEK1/2 inhibitor, U0126. Although both PD98059 and U0126
are widely used as specific MEK1/2 inhibitors, they differ in their
modes of action, substrate affinity and efficacy. For example,
PD98059 inhibits phosphorylation of MEK1/2 by Raf-1 [42],
while U0126 inhibits MEK1/2 kinase activity directly [43]. In
preliminary studies, cells were pre-treated with 2.5, 5.0 or 10 mM
U0126. Reductions in ERK activation were observed with pre-
treatments of 2.5 and 5.0 mM in replicated assays, but consistent
inhibition was observed only at 10 mM U0126 (not shown).
As shown in Figure 3A, U0126 – like PD98059 – inhibited
background ERK phosphorylation and TGF-b1-induced ERK
phosphorylation in ASE cells. Pre-treatment with U0126 resulted
in only moderate inductions at 6 h and 24 h in response to TGF-
b1 relative to TGF-b1 alone (Figure 3B). By 48 h, however, when
TGF-b1-induced NOS expression was reduced relative to the peak
for TGF-b1 alone at 24 h, U0126 pre-treatment maintained TGF-
b1-dependent NOS expression (Figure 3B).
Differences in the persistence of ERK activation (Figures 1B,
1C) and sensitivity to PD98059 (Figures 2A, 2B) noted in
comparisons of A. stephensi and A. gambiae cells suggested that the
differences in timing of the effects of U0126 in ASE cells
(Figure 3B; 48 h) versus the effects of PD98059 in 4a3B cells
(Figure 2D; 6 h) could be attributed to differences in inhibitor
modes of action and efficacy as well as to species-specific
differences in TGF-b1 responsiveness. Despite these differences,
Figure 1. Human TGF-b1 induced ERK phosphorylation in Anopheles cells in vitro and in vivo. (A) Anopheles stephensi ASE cells were
treated with PBS (0) or human TGF-b1 at concentrations from 6–6000 pg/mL. ERK phosphorylation (pERK) was examined by western blotting at 5 min
after treatment. Total ERK levels provided an assessment of protein loading and were used to normalize corresponding pERK levels. The fold increases
in ERK phosphorylation from densitometry analyses are indicated relative to the PBS control. (B) ASE cells were treated with 6000 pg/ml TGF-b1 for
the times indicated; the 0 h timepoint indicates the pre-treatment baseline. The fold increases in ERK phosphorylation from densitometry analyses
are indicated relative to 0 h baseline. (C) Anopheles gambiae 4a3B cells were treated with 60 pg/ml TGF-b1 or equivalent volumes of PBS for 5, 15, 30,
60 min. The fold increases in ERK phosphorylation from densitometry analyses are indicated relative to the matched PBS control within each
timepoint. (D) Female A. stephensi were allowed to feed on an artificial blood meal supplemented with 2–2000 pg/ml TGF-b1 or with an equivalent
volume of PBS as a control (BM). Midguts (n=100) were collected and processed for protein analysis at 20 min after completion of feeding. ERK
phosphorylation levels from densitometry were normalized to total ERK levels and fold inductions relative to the NBM (no blood meal) control are
indicated. Figures A–D are representative of immunoblots from 2–3 independent experiments.
doi:10.1371/journal.ppat.1000366.g001
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MEK-dependent and functioned to negatively regulate NOS gene
expression in both A. gambiae and A. stephensi cells.
ERK activation negatively regulates TGF-b1-induced
AsNOS expression in the midgut
Based on our observations that TGF-b1 induced ERK
phosphorylation in the midgut (Figure 1C) and that ERK signaling
negatively regulated NOS gene expression in vitro (Figures 2D, 3B),
we sought to determine whether ERK activation by TGF-b1
similarly regulated AsNOS gene expression in the A. stephensi
midgut. We first confirmed that PD98059 – which significantly
enhanced TGF-b1-induced NOS expression in vitro (Figure 2D) –
could be used to block ERK activation in vivo. Five day old female
A. stephensi were allowed to feed on artificial blood meals
supplemented with PBS as a control (BM) or with 2000 pg/mL
TGF-b1 with or without 4 or 40 mM PD98059. This dose of TGF-
b1 was selected to assess whether a feedback inhibition of NOS
induction in vivo that was attributed to NO synthesis [14] could
also derive from regulatory signaling. In replicated assays, we
observed that PD98059 dose-dependently inhibited ERK phos-
phorylation in the midgut within 20 min after blood feeding
(Figure 4A). PD98059 inhibited TGF-b1-induced ERK phosphor-
ylation with greater inhibition observed at 40 mM PD98059
(Figure 4A). Further, PD98059 action was ERK MAPK-specific –
that is, phosphorylation of JNK was not affected and phosphor-
ylation of p38 was only slightly affected by PD98059 in the A.
stephensi midgut (Figure 4A).
To determine whether ERK activation regulated TGF-b1-
induced NOS expression in vivo, we examined NOS gene expression
in A. stephensi midguts at 24 and 48 h after feeding, timepoints
within the range of ERK-dependent effects on NOS expression
ASE cells in vitro (Figure 3B). At 24 h, ingested TGF-b1 induced
NOS expression up to 1.7-fold compared with the PBS control
group (Figure 4B). However, in the presence of 40 mM PD98059,
which reduced ERK activation in the midgut (Figure 4A), TGF-
b1-induced NOS expression was increased 1.5-fold relative to
treatment with TGF-b1 alone (Figure 4B; p=0.068). This less
efficient enhancement of NOS induction by PD98059 in vivo
(Figure 4B) relative to that observed in vitro (Figure 2D) might be
due to the less efficient reduction in ERK activation by 40 mM
PD98059 in vivo (Figure 4A) relative to that observed in vitro
(Figure 2A). At 48 h after feeding, there was no detectable effect of
PD98059 on TGF-b1-induced NOS expression (Figure 4B).
Interestingly, we also observed a trend toward increased NOS
expression in PD98059-treated mosquitoes relative to the PBS
Figure 2. PD98059 inhibition of ERK phosphorylation increased TGF-b1-induced NOS expression in Anopheles cells. (A) The MEK1/2
inhibitor PD98059 dose-dependently inhibited TGF-b1-dependent ERK phosphorylation in 4a3B cells. Cells were pre-treated with PD98059 for 40 min
then treated with 60 pg/ml human TGF-b1 for 15 min. Cell lysates were analyzed by western blotting using anti-phospho-ERK or anti-ERK antibody.
(B) PD98059 inhibited TGF-b1-dependent ERK phosphorylation in ASE cells. Cells were pre-treated with PD98059 at 4 or 10 mM for 40 min then
treated with 6000 pg/ml TGF-b1 for 5 min. Cell lysates were subjected to western blot analysis as in (A). (C) Inhibition of ERK phosphorylation in 4a3B
cells is persistent. 4a3B cells were pre-treated with 4 mM PD98059 or with an equivalent volume of dimethyl sulfoxide (DMSO; PD98059 diluent) then
treated with 60 pg/ml TGF-b1 for 5 min to 6 h. Cell lysates were subjected to western blotting analysis as in (A). Immunoblots in A–C are
representative of 2–3 independent experiments. (D) PD98059 reversed the inhibitory effect of ERK activation on TGF-b1 induced NOS expression.
4a3B cells were pre-treated with 4 mM PD98059 or an equivalent volume of DMSO, then treated with 60 pg/ml TGF-b1. An additional control group
was treated with PBS (TGF-b1 diluent) at a volume equivalent to the TGF-b1 treatment. The data are represented as means6standard errors from
three independent experiments. The data were analyzed using ANOVA for overall significance and by Student-Neuman-Keuls for multiple pairwise
comparisons. Legend: *=p,0.05 (TGF-b1+PD98059 versus all other groups).
doi:10.1371/journal.ppat.1000366.g002
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basal ERK phosphorylation and TGF-b1-induced ERK phosphorylation. ASE cells were pre-treated with 10 mM U0126 for 40 min then treated with 6 or
6000 pg/ml TGF-b1 or an equivalent volume of PBS. ERK phosphorylation (pERK) was examined by western blotting at 5 min after treatment; total
ERK levels provided an assessment of protein loading. The immunoblot is representative of 3 independent experiments. (B) U0126 enhanced hTGF-
b1-induced AsNOS expression. ASE cells were pre-treated with 10 mM U0126 then treated with 6 pg/ml TGF-b1 for 6, 24 and 48 h. DMSO and U0126
alone had no impact on AsNOS expression compared to the PBS control (not shown). AsNOS expression was analyzed by quantitative reverse
transcriptase-polymerase chain reaction (qRT-PCR) assay. The data are represented as means6standard errors from three independent experiments
for fold inductions compared with the PBS control. The data were analyzed by ANOVA for overall significance and Student’s t-test was used for the
pairwise comparison at 48 h.
doi:10.1371/journal.ppat.1000366.g003
Figure 4. PD98059 inhibited TGF-b1-induced ERK phosphorylation and enhanced TGF-b1-induced NOS expression in the A.
stephensi midgut. (A) PD98059 inhibited ERK activation in mosquito midgut. Anopheles stephensi mosquitoes were fed on artificial bloodmeals
supplemented with 2000 pg/ml TGF-b1 with or without 4 or 40 mM PD98059. At 20 min after completion of feeding, 100 midguts from each
treatment group were dissected and prepared for immunoblot analysis. Protein lysate concentrations were measured by BCA assay; equal amounts of
protein were loaded in each lane. The immunoblot is representative of 3 independent experiments. (B) Inhibition of ERK phosphorylation enhanced
TGF-b1-induced NOS expression in vivo. Anopheles stephensi were fed on artificial bloodmeals supplemented with 40 mM PD98059 (PD), 2000 pg/ml
TGF-b1, or 40 mM PD98059 and 2000 pg/ml TGF-b1 (TGF-b1+PD). A control group (BM) was provided an identical unsupplemented artificial
bloodmeal. Previous studies confirmed that provision of small volumes of PBS and DMSO has no effect on AsNOS expression in vivo (not shown), so
these treatments were not included here. AsNOS expression levels were analyzed from midguts (n=15) collected at 24 h or 48 h after blood feeding
from each treatment group. The data are represented as means6standard errors from 5 independent experiments for fold inductions compared with
the PBS control. The data were analyzed by ANOVA for overall significance and Student’s t-test was used for the pairwise comparison at 24 h.
doi:10.1371/journal.ppat.1000366.g004
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activation may function to keep NOS expression in check in vivo.
ERK activation regulates P. falciparum development
In a previous study, we reported that low doses (2 and 200 pg/
mL) of human TGF-b1 provided by artificial blood meal reduced P.
falciparum oocystnumbers or infection intensity in A. stephensi, while a
high dose (2000 pg/mL) had no effect on infection intensity relative
to control mosquitoes [13]. This anti-parasite effect appeared to
depend in part on sustained induction of NOS over time at low dose
compared to high dose TGF-b1 [14]. Based on our findings that
inhibition of ERK phosphorylation enhanced TGF-b1-inducible
NOS expression in vivo (Figure 4B), we hypothesized that ERK
activation plays a pivotal role in TGF-b1-mediated control of
malaria parasite development in the mosquito and that the dose-
dependency of ERK activation blocks the anti-parasitic effects of
TGF-b1 at the highest dose of this cytokine.
Prior to addressing these hypotheses, we sought to determine
whether the effects of PD98059 were specific to the mosquito host.
In our assays of PD98059 activity in vivo,4mM PD98059 reduced
ERK activation, but 40 mM was required to reduce TGF-b1-
induced activation of ERK to near background levels (Figure 4A).
In addition, this higher dose enhanced TGF-b1-dependent NOS
induction in the A. stephensi midgut at 24 h (Figure 4B). As such, we
analyzed the effects of both low and high doses of PD98059 – as
well as TGF-b1 and the combined treatment – using a standard in
vitro assay of P. falciparum asexual stage growth.
In replicated assays, 10 nM chloroquine had no effect on P.
falciparum growth relative to the PBS control, while 100 nM
chloroquine significantly reduced parasite growth (Figure 5). These
effects were expected and confirmed that the assay was functioning
properly. Neither DMSO nor TGF-b1 at the doses tested had a
significant effect on parasite growth relative to the PBS control
(Figure 5). PD98059 had no effect on parasite growth at the lower
doses tested (0.4 and 4 mM), but 40 mM PD98059 reduced the
number of P. falciparum-infected RBCs relative to the PBS control.
There was no difference in the effects of 40 mM PD98059 and the
combined treatment (40 mM PD98059+2000 pg/ml TGF-b1) on
the number of infected RBCs, indicating that the effects of the
combined treatmentwerelikely duetoPD98059 (Figure 5).Because
our data confirmed that inhibition of ERK activation was maximal
at 40 mM PD98059 (Figure 4A) and that this dose enhanced TGF-
b1-dependent NOS induction in the A. stephensi midgut (Figure 4B),
we chose 40 mM PD98059 for our mosquito infection studies.
Although the growth assay utilized here has not been adapted to P.
falciparum sporogonic stages, which are metabolically distinct from
asexual stages [44], we acknowledged that infection phenotypes in
our studies could represent a combination of inhibitor effects on the
mosquito host and on P. falciparum.
For our infection studies, 3–5 day old A. stephensi were fed on P.
falciparum-infected erythrocytes supplemented with 2000 pg/mL
TGF-b1, with 40 mM PD98059, or with both treatments. At 8 day
after feeding, P. falciparum oocysts were counted on dissected midguts
to assess infection intensity (mean oocysts per midgut) and prevalence
(percentage of mosquitoes with midguts with at least one oocyst).
Infection intensity data from eight separate experiments were
analyzed by two-way ANOVA for the main effects of experiment
and treatment and by Student-Neuman-Keuls for means separa-
tion. Significant effects were noted for experiment (F=68.46,
df=7, p,0.0001) and treatment (F=11.97, df=3, p,0.0001) as
well as for the interaction of experiment and treatment (F=6.85,
df=21, p,0.0001). These results indicated that the data could not
be combined for analysis. However, means separation (a=0.05)
revealed that some data sets were not significantly different from
one another and this pattern tended to reflect a separation of low
and high infection intensities (Table 1). Specifically, data sets with
means of fewer than 10 oocysts in the controls (PBS; Experiments
1–6) grouped together, while the data sets with infection intensity
means of 17.42 and 49.50 in the controls (Experiments 7 and 8)
were significantly different from the other data sets. We discuss
here several trends associated with these groups.
At high infection intensities – which had treatment means
comparable to our previous studies [13] – 2000 pg/ml TGF-b1h a d
no effecton infectionintensityrelative to the controlgroup (Table 1;
1 vs 3 in Experiments 7 and 8) in accord with our published results.
Intriguingly, however, 2000 pg/ml TGF-b1 at low infection levels
significantly reduced infection intensity relative to controls in half of
the data sets (Table 1; 1 vs 3 in Experiments 1–6), suggesting that
control of infection by TGF-b1 may vary with P. falciparum oocyst
load. Additional treatment differences associated with infection
levels were notable. Specifically, PD98059 treatment alone
decreased infection intensity at both low and high infection
intensities (Table 1; 1 vs 2). And, in 4 of 6 experiments with low
infection intensities and in 1 of 2 experiments with high infection
intensities (Table 1; 3 vs 4), PD98059 enhanced TGF-b1-mediated
control of P. falciparum oocyst development. Finally, at low infection
intensities, the addition of PD98059 to TGF-b1 significantly
increased the prevalence of uninfected mosquitoes relative to that
in the TGF-b1 only treatment group in 3 of 6 experiments,withone
combined treatment group completely lacking infected mosquitoes
(Table 2). Despite a decrease in infection intensity in Experiment 8
(Table1;3 vs4),therewasnosignificanteffectofthecombination of
TGF-b1 and PD98059 on prevalence of uninfected mosquitoes at
this high infection intensity (not shown).
Discussion
In mammals, NOS expression is controlled by multiple signaling
pathways that can activate or inhibit gene expression and enzyme
Figure 5. Effect of treatments on growth of asexual stage
Plasmodium falciparum. Replicated cultures of P. falciparum NF54
were divided into treatment and control groups with 4 replicates per
group and incubated for 50 h with the indicated treatments. The
volume of PBS was equivalent to that used for TGF-b1 treatments.
Parasite growth was analyzed as described in the Materials and
Methods. Relative growth is compared to the PBS control which is
indicated as 100%. The data are represented as means and were
analyzed using ANOVA for overall significance and by Student-Neuman-
Keuls for multiple pairwise comparisons. Different lower case letters
indicate differences (p,0.05) among treatment groups.
doi:10.1371/journal.ppat.1000366.g005
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malaria infection, TGF-b1 has been reported to regulate both
early pro-inflammatory responses that function to clear parasites
and later anti-inflammatory responses that function to shut down
and resolve the host response to infection (reviewed in [46]). A
primary target of this regulation is NOS [46]. Analogously, TGF-
b1 also controls mosquito NOS expression, an important anti-
parasite response in this host as well [4,13,14]. Specifically, low
doses of TGF-b1 were observed to reduce P. falciparum infection in
A. stephensi, a response that was consistent with NOS induction, but
at high doses, there was no effect on infection [13,14]. Feedback
inhibition of NOS by NO at high treatment doses of TGF-b1i s
partly responsible for this effect [14]. However, based on the
complexity of the effects of TGF-b1 and the regulation of the
multiple signaling cascades by TGF-b1, we also hypothesized that
an inhibitory signaling pathway may be dose-dependently
activated to reduce NOS expression at higher doses of TGF-b1.
Several studies prior to our work have implicated the
involvement of MAPKs in mosquito innate immune responses.
For example, Mizutani et al. [47] reported that a JNK-like protein
was required for phagocytosis of heat-killed bacteria in Aedes
albopictus C6/36 cells. In the same cells, Chen-Chih Wu et al. [48]
reported that a p38 MAPK is required for the induction of
defensin mRNA and protein after bacterial challenge. Neverthe-
less, no direct evidence for MAPK signaling control of malaria
parasite development in Anopheles has been reported.
In this study, we provide the first evidence that ingested human
TGF-b1 regulates anti-parasite immunity in two different malaria
vector species through a conserved MAPK module – the MEK-
ERK signaling pathway. We propose in our model that MEK-
ERK signaling controls TGF-b1-mediated NOS gene expression
and P. falciparum development (Figure 6). Indeed, mosquitoes
treated with the MEK1/2 inhibitor PD98059 and human TGF-b1
showed higher NOS gene expression and evidence of lower
infection intensity at low infection levels or oocyst loads, suggesting
that MEK-ERK signaling negatively controls mosquito innate
immunity and thus favors parasite development. Inhibition of
ERK activation also reduced P. falciparum infection prevalence in
the presence of TGF-b1 to a greater degree at low infection levels,
suggesting that ERK activation also tunes the mosquito host
response to parasite infection. Although our present and previous
works support a role for NOS in these events, we suggest that a
suite of MAPK-regulated anti-parasite genes, some of which are
TGF-b1-dependent, may collectively contribute to the control the
parasite development in A. stephensi (Figure 6).
Under natural conditions, oocysts in field-collected A. gambiae
rarely number more than five, indicating that the observed effects
on prevalence at low infection levels would be relevant to natural
conditions. Given that a single oocyst can yield an infective
mosquito, only a reduction in prevalence – to near zero – can
impact malaria transmission [49,50]. Although the combined
treatment at low infection levels reduced prevalence to zero in only
one experiment (Table 2), we suggest based on trends here and the
pace of development of MAPK inhibitors (e.g., [51]) that more
specific and potent inhibition of MAPK signaling in the mosquito
is possible and can yield efficient and consistent inhibition of
parasite development.
Our results confirmed that P98059 and U0126 inhibit ERK
activation and anti-parasite NOS induction in A. stephensi by TGF-
b1 – a blood-derived cytokine that regulates P. falciparum infection
[13] but that has no direct effects on parasite growth (Figure 5).
However, the role of the parasite – and the possible effects of
PD98059 on the parasite – cannot be discounted in interpreting
the observed phenotypes (Tables 1 and 2). Malaria parasite
infection in the mosquito is density-dependent [50] and this
phenomenon likely contributes to the observed differential
Table 1. Treatment effects and trends for mean P. falciparum oocysts per midgut by experiment.
Mean oocysts per midgut by treatment Trends
















































B (1)=(3) (1).(2) (3).(4)
1Lower case letters indicate significant differences among experiments (all data combined) by ANOVA and Student-Neuman-Keuls test (a=0.05). For Experiments 3 and
5, a total of 20 mosquitoes were dissected per treatment group. For Experiments 1, 2, 4, 6, 7, and 8, a total of 50 mosquitoes were dissected per treatment group.
2Upper case letters indicate significant differences among treatment groups within an experiment by ANOVA and Student-Neuman-Keuls test (a=0.05).
doi:10.1371/journal.ppat.1000366.t001
Table 2. Prevalences of mosquitoes without P. falciparum
oocysts by experiment after feeding on infected blood
supplemented with TGF-b1 or with TGF-b1 and PD98059.
Uninfected mosquitoes (% total dissected)
Experiment TGF TGF+PD P-value
2 PD q uninfecteds?
1
a1 23 (46%) 43 (86%) ,0.0001 YES
2
ab 46 (92%) 38 (76%) 0.0291 NO
3
ab 14 (70%) 13 (65%) NS NO
4
ab 19 (38%) 35 (70%) 0.0013 YES
5
ab 13 (65%) 20 (100%) 0.0036 YES
6
b 10 (20%) 5 (10%) NS NO
1Lower case letters indicate significant differences among experiments (all data
combined) by ANOVA and Student-Neuman-Keuls test (a=0.05).
2Two-tailed p-values calculated by chi-square test (a=0.05).
doi:10.1371/journal.ppat.1000366.t002
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MAPKs could be so abundant at higher infection levels as to
overwhelm the effects of TGF-b1 and the combined treatment. As
for the effects of PD98059 on the parasite, multiple studies have
concluded that P. falciparum completely lacks the signaling modules
for the MAPKs ERK, p38 and JNK [52,53], but detailed studies
of the effects of MAPK inhibitors on sporogonic parasites have not
been completed. Despite this lack of knowledge, a reduction in
parasite intensity only due to a direct effect of PD98059 on P.
falciparum should be exhibited as proportional reductions in
intensity at low and high infection levels. However, parasite
intensity was reduced by 64% at high infection levels compared to
23% at low infection levels, suggesting that mosquito ERK
signaling – which is likely to be proportionately greater at higher
infection levels – is, in fact, contributing to the observed
phenotypes.
In mammalian cells, conserved MAPK signaling pathways are
critical to the regulation of anti-malarial immunity. Notably,
phagocytosis of P. falciparum infected erythrocytes by human
monocytes requires clustering of CD36 and activation of ERK and
p38 phosphorylation [54]. In addition, P. falciparum free merozoites
can inhibit human dendritic cell maturation via activation of ERK
and IL-10 production [55].
The regulation of TGF-b1-induced gene transcription by
MEK-ERK signaling has been reported in various mammalian
cell types [22,56–58]. In mammalian cells, TGF-b1 regulates gene
expression through both SMAD- dependent and SMAD-indepen-
dent pathways that coordinately control transcription factors and
gene expression [59]. ERK activation in response to TGF-b1 can
positively or negatively regulate SMAD-induced gene transcrip-
tion [60–62]. From a mechanistic perspective, the effect of a
specific blockade of the ERK pathway on mosquito NOS
expression could be explained by the negative effect of ERK on
SMAD nuclear localization and gene transcription [63,64]. The
SMAD complex is required to induce TGF-b1-mediated gene
transcription and SMAD activities are regulated by several
extrinsic pathways including those involving the MAPKs
[22,27]. Four MAPK phosphorylation sites have been reported
in the linker region of the receptor SMADs. Mutation of these sites
promotes SMAD nuclear translocation and TGF-b1-induced gene
expression [61,65]. Interestingly, a recent study revealed that a
MAPK-like protein modulates bone morphogenic protein signal-
ing and Mad-dependent gene expression in Drosophila melanogaster
[66]. Taken together, our data suggest that MAPK regulation of
TGF-b signaling is conserved in invertebrates and that the role of
this regulation in innate immunity to malaria parasite infection
may have deep evolutionary roots.
In mammals, TGF-b1 and the parasite factors P. falciparum
glycosylphosphatidylinositols (GPIs) and hemozoin are key activa-
tors of the MAPKs and, hence, innate immunity during infection.
In particular, parasite GPIs induce the activation of ERK, p38 and
JNK and the secretion of TNF-a in murine macrophages [24].
Hemozoin enhances IFN-c-dependent induction of NOS and NO
synthesis through activation of ERK and NF-kB [67]. Hemozoin
and P. falciparum GPIs also activate ERK signaling in mosquito
cells [32,33,68]. However, ERK activation is required – and,
therefore, a positive regulator – for Anopheles NOS induction by
human insulin and by P. falciparum merozoites [33]. These
discordant observations suggest that integration of other signaling
cascades with ERK must be occurring to dictate the output of
mosquito NOS gene expression. In mammalian cells, such pathway
integration and segregation function to regulate the impact of
ERK signaling [69] and are, in fact, the likely mechanisms
whereby cells to respond to simultaneous, possibly divergent
signals in a coordinated manner. Unraveling the likely interactions
of the mosquito MAPKs with other signaling pathways – which is
portended by MEK-ERK signaling complexity in mammalian
cells – is a focus of our ongoing studies.
Our data have demonstrated that chemical inhibitors com-
monly used in mammalian cells can be applied to study signaling
pathways in mosquito cells both in vitro and in vivo.T h eM A P K s
are an intense current focus for drug development for human
genetic and infectious diseases. As such, small molecule agonists
and antagonists as well as immunomodulatory peptides are being
developed at a pace such that we believe that the possibility exists
that these molecules could be used to further unravel MAPK
regulation of mosquitoinnateimmunity. Further,peptideagonists
or antagonists could be adapted in a transgenesis strategy to
specifically activate or disable critical mosquito MAPK pathways
to enhance anti-parasite resistance, a strategy that is of interest as
a novel approach to controlling malaria parasite transmission
[12].
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Figure 6. A model of MEK-ERK signaling in TGF-b1-dependent
control of P. falciparum development. Human TGF-b1 ingested
during the blood meal activates MEK-ERK signaling in mosquito cells.
Activation of ERK inhibits NOS gene expression which reduces nitric
oxide synthase levels and the synthesis of reactive oxygen and nitrogen
species. MEK-ERK signaling may inhibit the expression of other anti-
parasite genes as well that function together with NOS to limit parasite
development. Inhibition of the expression of NOS and other anti-
parasite gene products would favor P. falciparum development in the
mosquito midgut. In contrast, inhibition of MEK-ERK signaling by the
MEK inhibitors PD98059 or U0126 increases anti-parasite activity,
including TGF-b1-dependent NOS gene expression. Increased NOS
expression results in higher nitric oxide synthase enzyme levels and the
generation of inflammatory levels of reactive oxygen and nitrogen
species [7] that are toxic to the parasite.
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